3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
6
Phase 3
3
Phase 4
2
Phase 1
2
Phase NA
1
Phase 2/3
1
Phase 1/2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
11
Uterine Cervical Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Sexual Dysfunctions, Psychological
1
Premenopausal Breast Cancer
1
Ovarian Neoplasms
1
Neoplasms by Site
1
Neoplasms
1
Neoplasm Metastasis
1
Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
1
Hereditary Sensory and Autonomic Neuropathies
1
Head and Neck Neoplasms
1
Endometrial Neoplasms
1
Breast Diseases
1
Interventions
pembrolizumab
43
Nivolumab
24
Gemcitabine
23
Cyclophosphamide
21
Paclitaxel
17
Capecitabine
16
fludarabine
14
Ipilimumab
14
aldesleukin
11
Docetaxel
11
130-nm albumin-bound paclitaxel
11
Trastuzumab
10
Cetuximab
10
Bevacizumab
10
Albumin-Bound Paclitaxel
9
fludarabine phosphate
8
Specimen Handling
8
Interleukin-2
8
Fluorouracil
8
Cisplatin
8
Biopsy
8
Radiosurgery
7
Oxaliplatin
7
Irinotecan
7
durvalumab
6
avelumab
6
Temozolomide
6
Pemetrexed
6
Leucovorin
6
Carboplatin
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Neoplasm Metastasis
×
exemestane
×
Clear all
NCT00905021
2020-07-24
EXTENT
Baylor Breast Care Center
Phase 1/2
Terminated
4 enrolled
6 charts